GranuFlo Lawsuit Consolidation Concentrates Litigation in Massachusetts Federal Court, Reports Audet and Partners, LLP

Share Article

In a Transfer Order issued last month, the United States Judicial Panel on Multidistrict Litigation has consolidated federal claims alleging injuries arising from GranuFlo or NaturaLyte administration during hemodialysis.

By concentrating discovery and other fact gathering in the situs closest to Fresenius headquarters, we can more efficiently uncover the truth of what has transpired regarding these allegedly dangerous drugs.

On March 29, 2013, the United States Judicial Panel on Multidistrict Litigation ("JPML"), consolidated eleven pending federal actions alleging injuries related to GranuFlo and/of NaturaLyte administration during dialysis treatment.* These actions will now be heard as consolidated actions in the United States Federal Court for the District of Massachusetts. In addition to the named pending federal actions, the JPML noted more than thirty additional actions pending throughout the country which, the Panel believes, will also be facilitated by consolidating the federal actions in Massachusetts*.

William Audet, an attorney with Audet and Partners, LLP, a national trial firm representing several plaintiffs with injuries allegedly caused by administration of the GranuFlo and/or NaturaLyte products, is pleased to be moving these cases forward in the newly-formed Multidistrict Litigation: "By concentrating discovery and other fact gathering in the situs closest to Fresenius headquarters, we can more efficiently uncover the truth of what has transpired regarding these allegedly dangerous drugs. As the FDA has done previously**, we look forward to delving into existing documentation and evidence to provide further substantiation to our claims," states Mr. Audet.

Fresenius, the manufacturer of the GranuFlo and NaturaLyte products, has been under scrutiny since a November 2011 internal memorandum surfaced noting an alarming spike in the number of patients treated with GranuFlo or NaturaLyte who were dying from cardiac arrest. Though Fresenius took action to alert its own clinics of this problem, they allegedly failed to warn doctors in clinics not owned by Fresenius***, leading to an eventual Class I recall of the products in March 2012**.

As noted previously by the FDA**, administration of both the Naturalyte and GranuFlo Liquid Acid Concentrates can lead to dangerously elevated serum bicarbonate levels during dialysis treatment. Such increased bicarbonate levels have been linked to a dangerous condition known as alkalosis that, when left untreated, can lead to cardiac arrest.

If you, or one close to you, may have suffered serious complications after having been administered GranuFlo or NaturaLyte during hemodialysis, you are urged to contact Audet and Partners, LLP at (800) 965-1461, or by visiting our website at http://www.granuflodialysisrisk.com.

About Audet and Partners, LLP

Audet and Partners, LLP is a national trial practice located in San Francisco, CA, founded by Attorney William M. Audet, a 2012 recipient of designation as Top Attorneys in San Francisco, and a multiple recipient of the SuperLawyer Award. Audet and Partners, LLP represents only plaintiffs in class actions and mass torts involving dangerous pharmaceuticals and defective medical devices, as well as other areas of complex litigation. You can learn more online at http://www.audetlaw.com.

** http://www.fda.gov/medicaldevices/safety/listofrecalls/ucm309990.htm

*** http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0

Share article on social media or email:

View article via:

Pdf Print

Contact Author

William Audet, J.D., L.L.M.
Follow us on
Visit website